Acellular Animal Vaccine for Bordetella Bronchiseptica-mediated Respiratory Infections

Value Proposition

This novel BcfA accellular vaccine can efficiently elicit protective immune responses without the risk of subsequent infection by the vaccine strain and disease, as is the case with the present commercially available vaccines for Bordetella respiratory infections.

Invention Summary

Inventors in the Microbiology and Immunology Department at Wake Forest School of Medicine have developed an acellular B. bronchiseptica vaccine comprised of the immunogenic BcfA (Bordetella colonization factor A) protein, which with remarkable efficacy establishes protective immunity in vivo against Bordetella infections.
Proof of concept has been established in an in vivo mouse model, and both passive and active immunization have been shown to induce complete protection from bordetellosis, greatly decreased bacterial burden, high antibody titers and markedly reduced pulmonary injury.

Competitive Benefits